Ascendis ready for new hires after FDA approval

For a long time, Ascendis has been preparing for the approval of growth hormone Skytrofa, and the company can now execute launch and expansion plans.

Photo: Kevin Grønnemann/MedWatch

Ascendis Pharma is chomping at the bit after securing a long-awaited approval for Transcon hGH, which will be marketed as Skytrofa. The company has already prepared launch plans to be initiated immediately.

"Today is the day we have been working towards for several years. Everything is in place for a successful launch, and for us to become the company we want to be. Not just in terms of Skytrofa, but with regards to building on the Transcon platform in the future," Jesper Høiland, Global Commercial Officer at the company, said at a teleconference about the ruling. He joined the firm in spring 2020.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs